Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

RenovoRx, Inc.

Country	United States
Founded	2012
IPO Date	Aug 26, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Shaun Bagai

Contact Details

Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States
Phone	650 284 4433
Website	renovorx.com

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$9.00
CIK Code	0001574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
Employer ID	27-1448452
SIC Code	2834

Key Executives

Name	Position
Shaun R. Bagai	Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.	Founder, Chairman of Board and Chief Medical Officer
Leesa Gentry	Chief Clinical Officer
Robert Strasser	Vice President of Operations and Research & Development
Ronald B. Kocak CPA, CGMA	Vice President, Controller and Principal Accounting Officer
Ryan Witt	Senior Vice President and Head of Corporate Strategy and Partnerships

Latest SEC Filings

Date	Type	Title
May 15, 2025	10-Q	Quarterly Report
May 15, 2025	8-K	Current Report
May 8, 2025	SCHEDULE 13G	Filing
May 7, 2025	SCHEDULE 13G	Filing
Apr 30, 2025	DEF 14A	Other definitive proxy statements
Apr 1, 2025	8-K	Current Report
Apr 1, 2025	10-K	Annual Report
Mar 31, 2025	NT 10-K	Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Feb 10, 2025	8-K	Current Report
Feb 10, 2025	424B5	Filing

View All SEC Filings